Search clinical trials for: PD1 antibody

Total 5619 results

Hospices Civils de Lyon

Unknown

Efficiency and Security of NIVOLUMAB Therapy in Obese Individuals With COVID-19(COrona VIrus Disease) Infection (NIVISCO)

Obesity, COVID-19 Infection

France
Shanghai HyaMab Biotech Co.,Ltd.

Recruiting

PE0116 and PE0105 Injection in Treatment of Patients With Advanced Solid Tumor

Locally Advanced/Metastatic Solid Tumors

China
Ningbo No. 1 Hospital
Zhejiang University

Recruiting

CD19 CAR-T Expressing IL-7 and CCL19 Combined With Anti-PD1 in RR-DLBCL

Diffuse Large B-cell Lymphoma

China
Akeso

Recruiting

A Trial of AK112 (PD1/VEGF Bispecific) in Combination With Chemotherapy in Patients With NSCLC

NSCLC

China
University of Cologne

Recruiting

Abscopal Effect of Radiotherapy and Nivolumab in Relapsed Hodgkin Lymphoma After Anti-PD1 Therapy (AERN)

Classical Hodgkin Lymphoma

Germany
Regeneron Pharmaceuticals
Sanofi

Completed

Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers

Malignancies

United States, Korea, Republic of, Australia, Ireland, United Kingdom
Allife Medical Science and Technology Co., Ltd.
Beijing Hospital; Henan Provincial People's Hospital; The First People's Hospital...

Unknown

A Study of PD1 Combined With DC-NK Cell in the Treatment of Solid Tumors

Solid Tumor
Sun Yat-sen University
Wuzhou Red Cross Hospital; Fifth Affiliated Hospital, Sun Yat-Sen University; Affiliated Cancer Hospital & Institute of Guangzhou Medical University and other collaborators

Recruiting

Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma

Nasopharyngeal Cancer | Chemotherapy | Radiotherapy | PD-1 Therapy

China
University of Chicago

Active, not recruiting

Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors

Solid Tumor

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Methylphenidate and Physical Activity to Reduce Cancer Related Fatigue Due to Anti PD1 Immunotherapy

Metastatic Malignant Neoplasm | Advanced Malignant Neoplasm | Recurrent Malignant Neoplasm

United States
Oslo University Hospital
Merck Sharp & Dohme LLC; Norwegian Cancer Society

Completed

Sequential Intranodal Immunotherapy (SIIT) Combined With Anti-PD1 (Pembrolizumab) in Follicular Lymphoma (Lymvac-2)

Follicular Lymphoma

Norway
Peking University

Unknown

PD1 Combined With Apatinib in Patients With Relapsed or Refractory NK/T Cell Lymphoma

NK/T-cell Lymphoma
Sarcoma Oncology Research Center, LLC

Recruiting

Talimogene Laherparepvec, Nivolumab and Trabectedin for Sarcoma (TNT)

Sarcoma

United States
Augusta University

Terminated

Gemcitabine and CT-011 for Resected Pancreatic Cancer

Pancreatic Neoplasms | Pancreatic Cancer | Pancreas Cancer | Cancer of the Pancreas | Neoplasms Pancreatic

United States
Nilogen Oncosystems
Henry Ford Health System

Unknown

Pilot Study of Nilogen 3D-EX and Its Ability to Predict Therapeutic Response to Anti-PD1 or Anti-PDL1 in NSCLC (NO3DEXPL)

Non Small Cell Lung Cancer

United States
Icahn School of Medicine at Mount Sinai

Recruiting

Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC

Non-Small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Recruiting

Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-small Cell Lung Cancer

Advanced Non Small Cell Lung Cancer

United States
Jason J. Luke, MD
Bristol-Myers Squibb

Recruiting

Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors

Melanoma | Carcinoma, Renal Cell | Unresectable Solid Tumors

United States
Shanghai Zhongshan Hospital

Active, not recruiting

Combined Therapy Using Oxaliplatin and Gemcitabine Chemotherapy, Lenvatinib and PD1 Antibody (JS001) for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma

Cholangiocarcinoma, Intrahepatic

China
Affiliated Cancer Hospital & Institute of Guangzhou...

Not yet recruiting

Biomarker Analysis of HIPEC Combined With PD1/PDL1 Inhibitor for Gastric Cancer With Peritoneal Metastasis

Gastric Cancer
NHS Greater Glasgow and Clyde
Merck Sharp & Dohme LLC; Cancer Research UK; University of Southampton; Queen's... and other collaborators

Unknown

Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1)

Pancreatic Neoplasms | Mesothelioma | Carcinoma, Non-small-cell Lung

United Kingdom
Fudan University

Unknown

Stereotactic Body Radiation Therapy Combined With Anti-PD-1 Antibody in Metastatic Triple Negative Breast Cancer

Metastatic Breast Cancer

China
Spanish National Health System
Carlos III Health Institute; Rovi Pharmaceuticals Laboratories

Terminated

Efficacy of a Low-Molecular-Weight Heparin (Bemiparin) in the Treatment of Chronic Foot Ulcers in Diabetic Patients

Diabetic Angiopathies | Foot Ulcer, Diabetic
University Hospital, Ghent
GZA Ziekenhuizen Campus Sint-Augustinus

Completed

A Phase II Trial of Stereotactic Body Radiotherapy With Concurrent Anti-PD1 Treatment in Metastatic Melanoma.

Melanoma

Belgium
Zhejiang Cancer Hospital

Unknown

Anlotinib in Combination With PD1 With Gemcitabine Plus(+)Cisplatin for Unresectable or Metastatic Biliary Tract Cancer

Biliary Tract Cancer

China
Beijing Tsinghua Chang Gung Hospital

Recruiting

Safety and Efficacy of Lenvatinib and Anti-PD1 Antibody Combined With Radiotherapy Neoadjuvant Treatment for Resectable Hepatocellular Carcinoma With PVTT

Hepatocellular Carcinoma

China
Ann & Robert H Lurie Children's Hospital of Chicago
Dana-Farber Cancer Institute; University of Calgary; Children's Hospital of Orange...

Recruiting

rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG

Diffuse Intrinsic Pontine Glioma | Diffuse Midline Glioma, H3 K27M-Mutant

United States
Yonsei University

Unknown

The Combination of Anti-PD-1 With Radiotherapy in Previously Untreated Metastatic Melanoma

Melanoma

Korea, Republic of
Parker Institute for Cancer Immunotherapy
Seres Therapeutics, Inc.

Completed

Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome Intervention (MCGRAW)

Metastatic Melanoma

United States
Cancer Institute and Hospital, Chinese Academy...

Recruiting

A Study of Camrelizumab Plus Apatinib as Consolidation Therapy in Non-Small Cell Lung Cancer Patients Treated With Chemoradiotherapy

Locally Advanced Non-Small Cell Lung Cancer

China
Robert L. Ferris, MD, PhD
Bristol-Myers Squibb

Recruiting

Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer

Head and Neck Squamous Cell Carcinoma (HNSCC)

United States
University of Milano Bicocca
Azienda Ospedaliera San Gerardo di Monza

Recruiting

Observational Retro-prospective Study on PD1/PDL1 Inhibitors Treatment Duration in Patients With NSCLC (I-STOP)

Non-small Cell Lung Cancer

Italy
Allife Medical Science and Technology Co., Ltd.
Beijing Hospital; The First People's Hospital of Yunnan Province/First People... and other collaborators

Unknown

A Study of PD1 Combined With Dc-cik in the Treatment of Solid Tumors (DC-CIK)

Solid Tumor
Anaveon AG

Recruiting

A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1).

Advanced Solid Tumor | Metastatic Melanoma | Melanoma (Skin) | Cutaneous Melanoma | Adult Disease

United States, Spain, Germany, France, Italy
Northwestern University
National Cancer Institute (NCI)

Recruiting

Vudalimab for the Treatment of Locally Advanced or Metastatic Anaplastic Thyroid Cancer or Hurthle Cell Thyroid Cancer

Locally Advanced Thyroid Gland Anaplastic Carcinoma | Metastatic Thyroid Gland Anaplastic Carcinoma | Metastatic Thyroid Gland Oncocytic Carcinoma

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
Bristol-Myers Squibb

Terminated

Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of Glioblastoma

Glioblastoma | Glioblastoma Multiforme

United States
Fondazione Policlinico Universitario Agostino Gemelli...

Recruiting

Evaluation of Skin Health and QoL in Pts Receiving Anti-PD1/PDL1/CTLA4 or CDK Inhibitors. (SkinHealth)

Melanoma | Kidney Cancer | Breast Cancer | Gastric Cancer | Lung Cancer | Bladder Cancer | Skin Cancer | Head Neck Cancer

Italy
University Hospital, Grenoble
Etablissement Français du Sang

Recruiting

Profiling of Circulating Immune Cells to Uncover Response Signatures to Anti-PD1 Immunotherapy in Melanoma Patients (PHENOMENAL)

Melanoma

France
Second Affiliated Hospital of Soochow University

Not yet recruiting

PRaG Regimens Rechallenge for Patients With Resistance to PD1/PD-L1 Inhibitors in Refractory Advanced Solid Tumors.

Metastatic Solid Tumor
iOx Therapeutics
Merck Sharp & Dohme LLC

Terminated

IMM60 and Pembrolizumab in Melanoma and NSCLC

Melanoma | Non-small Cell Lung Cancer

Spain, United States, United Kingdom
Assistance Publique - Hôpitaux de Paris

Recruiting

Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of Persistence (CAPTiRALL)

Acute Lymphoblastic Leukemia, in Relapse | B Acute Lymphoblastic Leukemia

France
Abramson Cancer Center of the University of Pennsylvania

Terminated

Serial [18F]Fluorodeoxyglucose ([18F]FDG )PET/CT as a Biomarker of Therapeutic Response in Anti-PD1/PDL1 Therapy

Non-Small Cell Lung Cancer (NSCLC)

United States
Second Affiliated Hospital of Guangzhou Medical...

Recruiting

Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors

Sarcoma | Cervical Cancer | Breast Cancer | Head and Neck Cancer | Gastric Cancer | Colorectal Cancer | Esophageal Cancer | Lung Cancer | Pancreas Cancer | Liver Cancer | Ovary Cancer

China
Shanghai Cell Therapy Group Co.,Ltd

Recruiting

Exploratory Study of MSLN-CAR T Cells Secreting PD1/CTLA-4 Nanoantibody for the Treatment of Advanced Solid Tumors

Solid Tumor

China
Regeneron Pharmaceuticals

Not yet recruiting

A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma

Melanoma
Fifth Affiliated Hospital, Sun Yat-Sen University

Unknown

Dynamic PET/CT Evaluated the Response of Neoadjuvant Anti-PD1 Combination With Chemotherapy for Ⅱa-Ⅲb NSCLC (DYNAPET)

Non-small Cell Lung Cancer Stage III | PET/CT | Non-small Cell Lung Cancer Stage II

China
Xinqiao Hospital of Chongqing
TCRCure Biopharma Ltd.

Unknown

HPV-E6-Specific Anti-PD1 TCR-T Cells in the Treatment of HPV-Positive NHSCC or Cervical Cancer

Cervical Cancer | Head and Neck Squamous Cell Carcinoma

China
Bristol-Myers Squibb

Completed

An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread

Melanoma | Non-Small Cell Lung Cancer | Advanced Cancer

Canada, United States, Australia, France, Italy, Spain, Finland, Germany, Norway, Poland, Sweden
Bristol-Myers Squibb

Completed

A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors

CANCER,NOS

France, Canada, United States, Switzerland, Spain, Italy
Gustave Roussy, Cancer Campus, Grand Paris

Recruiting

Neoadjuvant Treatment Associated With Maintenance Therapy by Anti-PD1 Immunotherapy in Patients With Resectable Head and Neck Mucosal Melanoma (IMMUQ)

Head and Neck Mucosal Melanomas

France

Search clinical trials for: PD1 antibody

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mongolia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations